Aptagen, LLC
V7t1 targeting VEGF-165 (ID# 7734)
DNA
VEGF-165
Protein
1.4 nM (reported value)
10% (v/v) human serum in TBSTE (TBSE containing 0.05% (v/v) of Tween-20).
24°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
V7t1 is a truncated DNA aptamer that targets both VEGF-121 and VEGF-165.
5'-dTpdGpdTpdGpdGpdGpdGpdGpdTpdGpdGpdApdCpdGpdGpdGpdCpdCpdGpdGpdGpdTpdApdGpdAp-3'
Nonaka,Y., Sode, K., and Ikebukuro, K.(2010) "Screening and Improvement of an Anti-VEGF DNA Aptamer." Molecules, 15, 215-225.
25
7900.16
248000
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Nonaka,Y., Sode, K., and Ikebukuro, K.(2010) "Screening and Improvement of an Anti-VEGF DNA Aptamer." Molecules, 15, 215-225.
Stejskalov?, Anna & Oliva, Nuria & J England, Frances & Almquist, Benjamin. (2019). Biologically Inspired, Cell-Selective Release of Aptamer-Trapped Growth Factors by Traction Forces. Advanced Materials. 1806380. 10.1002/adma.201806380.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.